NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Novo Nordisk forecasts 2025 sales growth will slow, citing increased competition for its obesity drug Wegovy and aligning ...

Find insight on Novo Nordisk, GSK and more in the latest Market Talks covering Health Care.

Danish healthcare company Novo Nordisk A/S (NVO)reported Wednesday that its fiscal 2024 net profit climbed 21 percent to 100.9 ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.